Story stocks tell tall tales; Better yarns than at any time since the dotcom bubble
February 26, 2014 Leave a comment
February 18, 2014 7:52 pm
Story stocks tell tall tales
By James Mackintosh
Better yarns than at any time since the dotcom bubble
Wall Street broking is based on the idea of telling stories to sell stocks. Depending how you measure it, the Street is spinning better yarns than at any time since the dotcom bubble.
There are 33 stocks in the S&P 500 with valuations which rely on belief in a financial fairy: they trade at more than both 10 times book value and sales and 20 times forward earnings. These are the “story stocks”, companies expected to grow whatever happens to the economic cycle. At the peak of the dotcom bubble there were only 25 such stocks, as few dotcoms met S&P’s conditions.
Broaden to the top 1,000, and things look a little less frothy: there are 84 stocks at more than 10 times book. That is the most since the dotcom bust, but at the peak in 2000 there were more than 200 stocks this expensive – a level which relies in most cases on a story of technological change.
Still, the willingness to buy into stories to such an extent is unusual, whether about social media (Twitter),biotech (Gilead), internet retailing (Amazon), low-cost computing (ARM Holdings) or payment systems (Visa).
This may reflect the frantic desire to find growth in a post-crisis environment where economies have stumbled. Story stocks able to grow, no matter what, look tempting.
The problem is not with the stories. The future of retailing is clearly online. Biotech has fast-track regulation and better results. Even social media seems, in some cases, to be coming up with something which resembles a business model. The problem is with the valuations, which leave no room for error.
Individually, each stock is exposed to plot twists, as LinkedIn (down a quarter since September) shows. Overall, story stocks face a threat from a strong economy, which would make growth easier to find at a lower price elsewhere. Even so, there will be plenty more if a true bubble develops; after identical returns to the past four years, the biotech sector more than doubled in the four months to March 2000. Maybe a happy ending awaits, for some.
